Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 252,093,904
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 42,108 M
  • Annual Income, $ 14,643 M
  • EBIT $ 20,791 M
  • EBITDA $ 23,562 M
  • 60-Month Beta 0.63
  • Price/Sales 5.95
  • Price/Cash Flow 14.38
  • Price/Book 9.80

Options Overview Details

View History
  • Implied Volatility 38.50% ( -0.06%)
  • Historical Volatility 86.98%
  • IV Percentile 21%
  • IV Rank 25.55%
  • IV High 70.99% on 04/08/25
  • IV Low 27.35% on 12/26/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 46,384
  • Volume Avg (30-Day) 124,465
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 1,193,588
  • Open Int (30-Day) 1,129,529

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate 0.95
  • Number of Estimates 5
  • High Estimate 1.01
  • Low Estimate 0.92
  • Prior Year 0.90
  • Growth Rate Est. (year over year) +5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.05 +25.33%
on 08/06/25
58.34 -3.22%
on 08/25/25
+2.52 (+4.67%)
since 07/29/25
3-Month
45.05 +25.33%
on 08/06/25
81.44 -30.67%
on 06/13/25
-13.00 (-18.72%)
since 05/29/25
52-Week
45.05 +25.33%
on 08/06/25
139.74 -59.59%
on 08/30/24
-78.02 (-58.02%)
since 08/28/24

Most Recent Stories

More News
Join Class Action to Recover Losses from Novo Nordisk A/S (NVO) - Contact Levi & Korsinsky Before September 30, 2025

New York, New York--(Newsfile Corp. - August 29, 2025) - If you suffered a loss on your Novo Nordisk A/S (NYSE: NVO) investment and want to learn about a potential recovery under the federal securities...

NVO : 56.46 (+0.62%)
Contact Levi & Korsinsky by September 30, 2025 to Join Class Action Against Novo Nordisk A/S (NVO)

New York, New York--(Newsfile Corp. - August 28, 2025) - If you suffered a loss on your Novo Nordisk A/S (NYSE: NVO) investment and want to learn about a potential recovery under the federal securities...

NVO : 56.46 (+0.62%)
Get a FREE 1-Year Subscription to Barchart Premier! Open and Fund a Plus500 Futures Account and Make a Trade

Barchart Premier provides futures traders with historical data, advanced charting, watchlists, & screeners to help make smarter decisions. Join 30M+ people worldwide who use Plus500!

Novo Nordisk A/S Sued for Securities Law Violations - Contact The Gross Law Firm Before September 30, 2025 to Discuss Your Rights - NVO

NEW YORK , Aug. 28, 2025 /PRNewswire/ --  The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).

NVO : 56.46 (+0.62%)
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

NEW YORK , Aug. 27, 2025 /PRNewswire/ --

NVO : 56.46 (+0.62%)
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

 

NVO : 56.46 (+0.62%)
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options

NVO : 56.46 (+0.62%)
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?

Eli Lilly & Company LLY and Pfizer PFE are both large-cap U.S. pharmaceutical giants with diversified drug portfolios and strong R&D pipelines. While Lilly boasts a leading presence in cardiometabolic...

NVO : 56.46 (+0.62%)
LLY : 732.58 (+0.08%)
PFE : 24.76 (+0.65%)
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

Amgen’s AMGN stock has risen 13.5% so far this year compared with an increase of 1.6% for the industry. The stock has also outperformed the sector and S&P 500 Index, as seen in the chart below.AMGN...

NVO : 56.46 (+0.62%)
LLY : 732.58 (+0.08%)
AMGN : 287.71 (+0.74%)
Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO

NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.

NVO : 56.46 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 57.57
2nd Resistance Point 57.05
1st Resistance Point 56.75
Last Price 56.46
1st Support Level 55.94
2nd Support Level 55.42
3rd Support Level 55.12

See More

52-Week High 139.74
Fibonacci 61.8% 103.57
Fibonacci 50% 92.39
Fibonacci 38.2% 81.22
Last Price 56.46
52-Week Low 45.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar